Ophthalmic fibreoptic-light instrument, single-use Australia - English - Department of Health (Therapeutic Goods Administration)

ophthalmic fibreoptic-light instrument, single-use

carl zeiss pty ltd - 45193 - ophthalmic fibreoptic-light instrument, single-use - this single use device is an accessory of carl zeiss phaco systems with posterior segment functionality. it has been designed to internally illuminate the eye bulb transmitting the light emitted by a xenon lamp.

Surgical procedure kit, ophthalmic, non-medicated, single-use Australia - English - Department of Health (Therapeutic Goods Administration)

surgical procedure kit, ophthalmic, non-medicated, single-use

carl zeiss pty ltd - 45150 - surgical procedure kit, ophthalmic, non-medicated, single-use - a collection of devices presented as a procedure pack are an accessory of refractive femtosecond lasers of carl zeiss meditec ag within the indication for use as defined for the respective device.

Manual intraocular lens injector, single-use Australia - English - Department of Health (Therapeutic Goods Administration)

manual intraocular lens injector, single-use

carl zeiss pty ltd - 47725 - manual intraocular lens injector, single-use - the single-use sterile injector is intended for the injection of soft intraocular lenses manufactured by carl zeiss meditec. (the lens must be loaded prior to insertion into the eye).

Medical image management system application software Australia - English - Department of Health (Therapeutic Goods Administration)

medical image management system application software

carl zeiss pty ltd - 60724 - medical image management system application software - stores customer data and to display data collected by zeiss devices

CARLEVENT levodopa/carbidopa/entacapone 150/37.5/200 mg tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

carlevent levodopa/carbidopa/entacapone 150/37.5/200 mg tablet bottle

medis pharma pty ltd - carbidopa monohydrate, quantity: 40.5 mg (equivalent: carbidopa, qty 37.5 mg); entacapone, quantity: 200 mg; levodopa, quantity: 150 mg - tablet, film coated - excipient ingredients: trehalose dihydrate; hyprolose; magnesium stearate; microcrystalline cellulose; sodium sulfate; carmellose sodium; powdered cellulose; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

CARLEVENT levodopa/carbidopa/entacapone 125/31.25/200 mg tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

carlevent levodopa/carbidopa/entacapone 125/31.25/200 mg tablet bottle

medis pharma pty ltd - carbidopa monohydrate, quantity: 33.75 mg (equivalent: carbidopa, qty 31.25 mg); entacapone, quantity: 200 mg; levodopa, quantity: 125 mg - tablet, film coated - excipient ingredients: trehalose dihydrate; microcrystalline cellulose; hyprolose; magnesium stearate; powdered cellulose; carmellose sodium; sodium sulfate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

CARLEVENT levodopa/carbidopa/entacapone 100/25/200 mg tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

carlevent levodopa/carbidopa/entacapone 100/25/200 mg tablet bottle

medis pharma pty ltd - entacapone, quantity: 200 mg; levodopa, quantity: 100 mg; carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg) - tablet, film coated - excipient ingredients: sodium sulfate; powdered cellulose; hyprolose; trehalose dihydrate; magnesium stearate; carmellose sodium; microcrystalline cellulose; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

CARLEVENT levodopa/carbidopa/entacapone 50/12.5/200 mg tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

carlevent levodopa/carbidopa/entacapone 50/12.5/200 mg tablet bottle

medis pharma pty ltd - entacapone, quantity: 200 mg; levodopa, quantity: 50 mg; carbidopa monohydrate, quantity: 13.5 mg (equivalent: carbidopa, qty 12.5 mg) - tablet, film coated - excipient ingredients: sodium sulfate; powdered cellulose; magnesium stearate; carmellose sodium; microcrystalline cellulose; trehalose dihydrate; hyprolose; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

CARLEVENT levodopa/carbidopa/entacapone 75/18.75/200 mg tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

carlevent levodopa/carbidopa/entacapone 75/18.75/200 mg tablet bottle

medis pharma pty ltd - levodopa, quantity: 75 mg; carbidopa monohydrate, quantity: 20.25 mg (equivalent: carbidopa, qty 18.75 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: sodium sulfate; hyprolose; carmellose sodium; microcrystalline cellulose; magnesium stearate; trehalose dihydrate; powdered cellulose; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

CARLEVENT levodopa/carbidopa/entacapone 200/50/200 mg tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

carlevent levodopa/carbidopa/entacapone 200/50/200 mg tablet bottle

medis pharma pty ltd - levodopa, quantity: 200 mg; carbidopa monohydrate, quantity: 54 mg (equivalent: carbidopa, qty 50 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: powdered cellulose; microcrystalline cellulose; sodium sulfate; carmellose sodium; magnesium stearate; hyprolose; trehalose dihydrate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.